Bellicum Pharmaceuticals Inc (BLCM) was Upgraded by Citigroup to ” Buy”. Earlier the firm had a rating of “Neutral ” on the company shares. Citigroup advised their investors in a research report released on Aug 9, 2016.
On the company’s financial health, Bellicum Pharmaceuticals Inc reported $-0.61 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.58.Analysts expectations of $ .06.During the same quarter in the previous year, the company posted $-0.40 EPS.
Bellicum Pharmaceuticals Inc closed down -0.31 points or -1.79% at $17.05 with 3,37,253 shares getting traded on Monday. Post opening the session at $17.5, the shares hit an intraday low of $16.86 and an intraday high of $17.8 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jul 29, 2016, Kevin M. Slawin (Chief Technology Officer) sold 15,000 shares at $15.00 per share price. According to the SEC, on Jul 29, 2016, David M. Spencer (Chief Scientific Officer) sold 10,000 shares at $15.00 per share price. On Jun 6, 2016, Annemarie Moseley (COO/EVP Clinical Development) sold 25,000 shares at $13.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Bellicum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer including hematological cancers and solid tumors as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system in real time. The Company is developing next-generation product candidates in the areas of cellular immunotherapy including hematopoietic stem cell transplantation (HSCT) chimeric antigen receptors (CAR) T cells therapy and dendritic cell vaccines. The Company’s product candidates include BPX-501 BPX-201 BPX-401 BPX-601 and BPX-701. It is also engaged in other development programs such as CIDeCAR for the treatment of solid tumors and CaspaCIDe TCR for the treatment of hematological cancers.